People across Asia flocked to shopping malls and online stores Friday as they scrambled to get their hands on the latest ...

After-date between Chun Jung-myung and lawyer Lee Yoo-jin, who made the final choice, will be revealed.Today, April 28 ...

A blind box from the latest series ... you do get the dopamine,” said 27-year-old collector Lawrence Yu, who lives in Melbourne, Australia and has so far spent $1,200 Australian dollars ...

From childhood best friends to sweethearts and everything in between, manhwa offers some of the most romantic stories online.

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

The KMT and TPP have provided “mutual legal assistance” by expressing support for corruption and document forgery, shamelessly gathering to pressure and threaten the judiciary. They opened a back door ...

The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.

Penpulimab-kcqx has been approved in China for two indications: 1. first-line treatment of advanced NPC, and 2. second or ...

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...

At the ongoing 2025 Beijing International Film Festival (BJIFF), an exhibition featuring over 150 hand-drawn posters by ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in ...